Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
tramadol hydrochloride
|
| gptkbp:approvalYear |
2005
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N02AX02
|
| gptkbp:brand |
tramadol hydrochloride extended-release
|
| gptkbp:contraindication |
severe respiratory depression
acute intoxication with alcohol concurrent use of MAO inhibitors |
| gptkbp:controlledSubstanceSchedule |
Schedule IV (US)
|
| gptkbp:discontinued |
United States (as of 2019)
|
| gptkbp:form |
extended-release tablet
|
| gptkbp:halfLife |
7-9 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ultram ER
|
| gptkbp:legalStatus |
prescription only (Rx)
|
| gptkbp:manufacturer |
gptkb:Janssen_Pharmaceuticals
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:riskFactor |
gptkb:serotonin_syndrome
addiction seizures |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
constipation dizziness headache |
| gptkbp:usedFor |
management of moderate to moderately severe chronic pain
|
| gptkbp:bfsParent |
gptkb:Biovail_Corporation
|
| gptkbp:bfsLayer |
7
|